Source comparison
Mechanistic Comparison Summary
Primary immune arm Adaptive (T-cell, NK, thymic) Innate (antimicrobial, neutrophil, DC activation) Primary receptor TLR2 / TLR9 on DCs, macrophages, T-cells FPR2, CXCR2/4; direct membrane disruption; EGFR T-cell biology Thymic maturation; naive output; Treg in
This comparison does not assign a generated winner or score.
- Primary immune arm
- Adaptive (T-cell, NK, thymic)
- Innate (antimicrobial, neutrophil, DC activation)
- Primary receptor
- TLR2 / TLR9 on DCs, macrophages, T-cells
- FPR2, CXCR2/4; direct membrane disruption; EGFR
- T-cell biology
- Thymic maturation; naive output; Treg induction; CD8+ CTL activation
- No direct T-cell receptor activity
- Direct antimicrobial
- None
- E. coli MIC 2–4 µg/mL; MRSA 4–8 µg/mL; biofilm disruption
- LPS neutralisation
- Indirect (IL-10, macrophage activation)
- Direct: lipid A binding Kd ~0.1 µM
- Antiviral
- Adaptive: IFN-α/β via pDC TLR7/9; CD8+ CTL; MHC-I upregulation
- Innate: direct virucidal; receptor blocking; TLR3-IFN-β
- Autoimmune use
- Treg-induction; consistently anti-autoimmune
- Concentration-dependent: anti-inflammatory (low) vs pro-autoimmune (high, via self-DNA/TLR9)
- Cancer biology
- Pro-immunogenic: anti-PD-1 synergy; TIL expansion
- Paradoxical: pro-tumour (some cancers) / anti-tumour (others) — context-dependent
- Sepsis mechanism
- Indirect: macrophage IL-10; Treg; 12–24h onset
- Direct: LPS neutralisation + immediate; bactericidal at focus
- Combination rationale
- Innate (LL-37 acute) + Adaptive (Tα1 sustained) — mechanistically orthogonal; optimal in infection + immunity endpoints
- 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Thymosin Alpha-1 and LL-37 for research and laboratory use. View UK stock →
- William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.